Cantor Fitzgerald keeps USD 15.00 target for Trulieve Cannabis stock
Published on 10/29/2026 at 14:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSCash flow and analyst view
- Cantor Fitzgerald retained an Overweight rating on October 23, 2026.
- Operating cash flow reached USD 53 million in the second quarter of 2026.
- Quarter-end cash stood at USD 325 million in the second quarter of 2026.
Trulieve Cannabis (ISIN US89790E1064) has a USD 15.00 analyst target from Cantor Fitzgerald. Business Insider reported on October 23, 2026, that the firm reiterated its Buy rating and price target.
Analyst support meets a large loss
The rating follows Trulieve's second-quarter report, where revenue reached USD 271 million and adjusted EBITDA came to USD 98 million. Benzinga reported that the quarter included a USD 406 million net loss, including a USD 407 million impact from the Harvest deconsolidation and equity investment.
What does the next report add?
The company generated USD 53 million in operating cash flow during the second quarter and held USD 325 million in cash at quarter-end, according to the same Benzinga transcript. That liquidity gives the upcoming report a clear operating test: whether medical-only revenue can remain stable after the business change.
Three dates frame the update
On August 7, 2026, Trulieve reported second-quarter revenue of USD 271 million. On October 6, 2026, Yahoo Finance published the company announcement for its November 5, 2026 results call at 8:30 a.m. Eastern Time. On October 23, 2026, Cantor Fitzgerald maintained the USD 15.00 target.
Results date and market view
The November 5, 2026 report is scheduled before the market opens, with the conference call at 8:30 a.m. Eastern Time. Trulieve Cannabis was trading at EUR 9.41 at Lang & Schwarz on October 29, 2026 at 2:06 p.m. CEST.
Trulieve Cannabis key data
- Company: Trulieve Cannabis Corp.
- ISIN: US89790E1064
- Ticker: TRLV
- Primary exchange: NYSE
- Price Lang & Schwarz (as of October 29, 2026, 2:06 p.m. CEST): EUR 9.41
- Market capitalization: USD 2.1 billion (as of October 21, 2026)
- Sector / Industry: Healthcare / Drug Manufacturers - Specialty and Generic
Market context: Market report S&P 500.
The further course of trading is shown by the continuously updated real-time quote of Trulieve Cannabis stock.
